Dive into the archives.
- Hot off the ECTRIMS Press…Alemtuzumab Shows Lasting Benefits in RRMS
(RTTNews) - Friday, biotechnology company Genzyme Corp. said that four-year follow-up data from its completed Phase [...]
- Hot off the ECTRIMS Press…Sanofi Oral is Promising
LONDON, Sept 11 (Reuters) – Patients given an experimental multiple sclerosis tablet from Sanofi-Aventis showed a significant improvement compared to those on placebo in a mid-stage test, researchers said on Friday.
Teriflunomide, which was used as an add-on therapy to interferon beta in the Phase II clinical trial, is one of a number of MS drugs [...]
- Hot off the ECTRIMS Press…Fewer Injection Site Reactions with Avonex
CAMBRIDGE, MA – Sept. 11, 2009 – Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon beta-1a IM) reported significantly fewer injection site reactions (ISRs) compared to patients on Betaferon (interferon beta-1b), Copaxone (glatiramer Acetate) or Rebif (interferon beta-1a). [...]
- Hot off the ECTRIMS Press…Cladribine Reduces Disease Activity in a Big Way
Darmstadt, Germany, September 11, 2009 – Merck KGaA announced today new data from a post-hoc analysis of the two-year (96-week) placebo-controlled CLARITY(1) Phase III trial using a short-course of Cladribine Tablets (the proprietary investigational oral formulation of cladribine) to treat patients with relapsing-remitting multiple sclerosis (MS). The data from this post-hoc analysis of the CLARITY [...]
- Hot off the ECTRIMS Press…Play Your Brain Games!
Is it really possible to improve some, MS related, cognition issues by playing computer games? Doctors from Baylor College of Medicine here in Houston seem to think so. According to their poster presentation at the World Congress on Treatment and Research in Multiple Sclerosis (ACTRIMS + ECTRIMS + LACTRIMS) Montreal, Quebec, Canada (Sept. 17-20, 2008) they conclude that [...]
- Hot off the ECTRIMS Press: Peptimmune Completes Ph 1b Study of PI-2301
Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009
CAMBRIDGE, Mass., Aug. 25 /PRNewswire/ — Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is [...]
